Press release
Cephalosporin Market Outlook 2024: Exclusive Report By The Business Research Company | Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company
Cephalosporin Market Trends
The Business Research Company offers in-depth market insights through Cephalosporin Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The cephalosporin market size has grown steadily in recent years. It will grow from $17.04 billion in 2023 to $17.69 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to growing prevalence of bacterial infections, increasing antibiotic resistance, expanding surgical procedures and hospitalizations, rising awareness among healthcare professionals, regulatory support for antibiotic development..
The cephalosporin market size is expected to see steady growth in the next few years. It will grow to $20.29 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to escalating global burden of infectious diseases, emerging bacterial resistance, continued growth in surgical interventions and healthcare-associated infections, increasing demand for broad-spectrum antibiotics, evolving reimbursement policies influencing market dynamics.. Major trends in the forecast period include technological advancements, regulatory landscape, market expansion with advance solution, collaborations and partnerships..
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13402&type=smp
Market Segmentation:
The main types of cephalosporin are branded and generic. A branded refers to cephalosporin antibiotics that are marketed and sold under a specific brand name by a pharmaceutical company and used to treat infections caused by susceptible bacteria. They are administered via injection and oral routes in treatment applications such as respiratory tract infections, skin infections, ear infections, urinary tract infections, sexually transmitted infections, and others.
Major Driver - Rising Prevalence of Infectious Diseases Fuels Cephalosporin Market Growth
The growing prevalence of infectious diseases is expected to propel the growth of the cephalosporin market going forward. Infectious diseases refer to illnesses caused by the invasion and multiplication of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can be transmitted from one individual to another through various means that cause diseases such as tuberculosis, malaria, and flu. Infectious diseases drive the demand for cephalosporin antibiotics, which are commonly used to treat infectious diseases caused by bacterial pathogens and can be prescribed for various types of infections due to their crucial role in managing and combating bacterial infections. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the growing prevalence of infectious diseases will drive the growth of the cephalosporin market.
Competitive Landscape:
Major companies operating in the cephalosporin market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan PLC, Baxter International Inc., Eisai Co. Ltd., Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Shionogi & Co Ltd, Cipla Inc.., Hikma Pharmaceuticals PLC, Lupin Ltd., Zydus Lifesciences Ltd., Alkem Labs Ltd., Aurobindo Pharma Ltd., Fresenius Kabi, Aristo Pharmaceuticals Ltd, Accord Healthcare Ltd., Mankind Pharma Ltd., Qilu Anti Pharmaceutical Co. Ltd., Shandong Ruiying Pioneer Pharmaceutical Co. Ltd, Vansen Pharma Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/cephalosporin-global-market-report
Top Trend - Advanced-Generation Therapies To Tackle Antibiotic Resistance
Major companies operating in the cephalosporin market are focused on developing new products and therapies, such as advanced-generation cephalosporins, to combat antibiotic resistance and enhance their portfolio's effectiveness in treating a wider spectrum of bacterial infections. Ceftobiprole is a broad-spectrum cephalosporin antibiotic used to treat various bacterial infections, including skin and soft tissue infections and pneumonia. For instance, in July 2022, Mast Group Ltd., a UK-based manufacturer and supplier of clinical and industrial diagnostic products, launched Ceftobiprole 5µg in the MASTDISCS Antimicrobial Susceptibility Test range. Ceftobiprole (Zevtera or Mabelio) is a broad-spectrum 5th-generation cephalosporin that is approved for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in several European countries. Ceftobiprole is a good alternative for targeted empirical therapy due to its broad range of activity, strong effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), and favorable safety profile.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Cephalosporin Market Characteristics
3. Cephalosporin Market Trends And Strategies
4. Cephalosporin Market - Macro Economic Scenario
5. Cephalosporin Market Size And Growth
…..
27. Cephalosporin Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cephalosporin Market Outlook 2024: Exclusive Report By The Business Research Company | Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company here
News-ID: 3435791 • Views: …
More Releases from The Buisness Research Company
Understanding Current Trends and Future Outlook in the Asbestos Market: Insights …
The asbestos market size has grown rapidly in recent years. It will grow from $1.07 billion in 2023 to $1.19 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to industrialization boom, military applications, construction and building industry growth, mining and export boom , automotive industry adoption.
The asbestos market size is expected to see…
Autonomous Train Components: Exploring the Global Market Trends in 2024
The autonomous train components market size has grown rapidly in recent years. It will grow from $4.83 billion in 2023 to $5.65 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to a rise in the development of monorails, government investment in rail infrastructure, growth in investment in smart cities, increased safety operational benefits, and increasing urbanization.
The…
Urban Mobility: Commuter Rail and Public Bus Services Market Insights 2024
The commuter rail and public bus services market size has grown strongly in recent years. It will grow from $401.19 billion in 2023 to $440.63 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increased urbanization, traffic congestion, environmental concerns, economic development, fuel price fluctuations, population density.
The commuter rail and public bus services market size…
3D Printing In Healthcare Market Analysis 2024 -2033: Forecasted Market Size, To …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through 3D Printing In Healthcare Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The 3d printing in healthcare market size has grown rapidly…
More Releases for Cephalosporin
Veterinary Cephalosporin Market to Witness Robust Expansion by 2024
LP INFORMATION offers a latest published report on Veterinary Cephalosporin Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Veterinary Cephalosporin market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular,…
Business Opportunities in Cephalosporin Market by 2023
Cephalosporin market was valued at $3,136 million in 2016, and is projected to reach $4,980 million by 2023, growing at a CAGR of 6.8% from 2017 to 2023. The third-generation cephalosporin segment held around one-third share of the total market in 2016.
Get sample copy of this report:https://www.alliedmarketresearch.com/request-sample/3510
The introduction of combination drugs such as multiple antibacterials or antibacterials combined with an inhibitor drives the market growth. The use of combination drugs…
Cephalosporin Market Strengths, Weaknesses; Key Players Analysis By QYResearchRe …
Qyresearchreports include new market research report “Global Cephalosporin Market Professional Survey Report 2018” to its huge collection of research reports.
This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
Union Chempharma
NCPC
Qilu Antibiotics
Lupin Pharmaceuticals
Hospira
Dhanuka Laboratories
Fukang
Dongying Pharmaceutical
Alkem
SALUBRIS
LIVZON
Hetero Drugs
CSPC
TEVA
Download Free exclusive Sample of this report: https://www.qyresearchreports.com/sample/sample.php?rep_id=1548552&type=S
The report on the global market for Cephalosporin has been prepared after conducting a fructuous analysis of several industries…
Global Cephalosporin Market Specifications, Analysis Forecast 2017 to 2022
Worldwide Market Reports added Latest Research Report titled "Global Cephalosporin Market Professional Survey Report 2018" to its Large Report database.
This report studies Cephalosporin in Global Market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
This report focuses on top manufacturers in global market, with production, price, revenue and market share…
Cephalosporin Market Growing $1,99,754 million by 2023
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea. The global cephalosporin market is estimated to reach $1,99,754 million by…
Global Cephalosporin Market Research, Analysis and Overview 2022
Qyresearchreports include new market research report "Global Cephalosporin Market Research Report 2017" to its huge collection of research reports.
The exhaustive report here gathers various viewpoints having a place with the general Cephalosporin market which verbalizes the present-day information and future exposures with reference to the dynamic forces at play. The prime purpose for the examination report is to offer the endorser with an expansive layout and make available the beneficial…
